Physician profile
Bashar Al Hemyari
NPI 1831550730
$1,490.13
in general payments reported to CMS, 2019-2025
25 companies · $67.99 in 2025
The $67.99 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.19 · 2020: $130 · 2021: $558 · 2022: $613 · 2023: $20.04 · 2024: $53.59 · 2025: $67.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $141.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $284.03 | 2019-2022 | |
| Abiomed | $137.13 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.56 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $97.60 | 2022-2024 | Xarelto |
| Grifols USA, LLC | $95.41 | 2021-2022 | |
| Philips North America LLC | $92.88 | 2022-2025 | Igt Devices Systems Undivided |
| Mallinckrodt Hospital Products INC. | $83.92 | 2021 | |
| Sanofi-Aventis U.S. LLC | $83.33 | 2022 | |
| Esperion Therapeutics, INC. | $69.34 | 2020-2022 | |
| Lantheus Medical Imaging, INC. | $68.79 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $57.94 | 2021 | |
| Boston Scientific Corporation | $57.61 | 2022-2024 | Bodyguardian |
| Alnylam Pharmaceuticals INC. | $42.03 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.95 | 2022-2024 | Lifevest |
| Chiesi USA, INC. | $27.85 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $27.47 | 2022 | |
| Akcea Therapeutics, INC. | $23.49 | 2020-2021 | |
| Celgene Corporation | $21.55 | 2019 | |
| Merck Sharp & Dohme LLC | $13.98 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $13.63 | 2019 | |
| Lundbeck LLC | $12.47 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.31 | 2021 | |
| Pfizer INC. | $12.13 | 2022 | |
| Amarin Pharma, INC. | $11.64 | 2021 | |
| Amryt Pharma Holdings Ltd | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Al Hemyari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.